Yea Christopher 4

4 · KalVista Pharmaceuticals, Inc. · Filed May 26, 2026

AI-generated summary of this filing

Updated May 26, 2026

KalVista (KALV) CDO Christopher Yea Sells 2,358 Shares to Cover Taxes

What Happened

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals (KALV), had 3,750 restricted stock units (RSUs) settle into 3,750 shares on May 21, 2026. Those shares were issued for no cash consideration.
On May 22, 2026, he sold 2,358 of those shares in an open-market transaction at $26.78 per share, generating $63,158 in gross proceeds. The sale was a sell-to-cover to satisfy tax withholding obligations (not a discretionary sale).

Key Details

Transaction dates: RSU settlement/exercise-conversion on 2026-05-21; open-market sale on 2026-05-22 at $26.78 per share.
Proceeds from sale: $63,158 (2,358 shares × $26.78).
Shares retained from this settlement: 3,750 received − 2,358 sold = 1,392 shares remaining from this vesting (filing does not state total company-wide holdings).
Footnotes: RSUs represent the contingent right to receive one share upon settlement for no consideration (F1). The sale was to cover tax withholding via a “sell-to-cover” (F2). Vesting schedule: 1/16th each quarterly anniversary starting May 21, 2025 (F3).
Filing timeliness: Form 4 filed 2026-05-26 reporting transactions dated 5/21–5/22; filing appears timely.

Context

This was a routine RSU settlement followed by a sell-to-cover tax withholding. The derivative activity reflects RSUs converting to shares (no cash cost); part of those shares were sold immediately to satisfy taxes rather than as a discretionary investment decision.
Such routine tax-related sales are common after equity awards vest and do not, by themselves, imply a change in insider sentiment.

Form 4

Period: 2026-05-21

CHIEF DEVELOPMENT OFFICER

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-05-21+3,750→ 231,117 total
Sale
Common Stock
[F2]
2026-05-22$26.78/sh−2,358$63,158→ 228,759 total
Exercise/Conversion
Restricted Stock Unit
[F1][F3]
2026-05-21−3,750→ 41,250 total
→ Common Stock (3,750 underlying)

Footnotes (3)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
[F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
[F3]1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date.

Signature

/s/ Benjamin L. Palleiko, Attorney-in-Fact|2026-05-26

1 file